To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

April 26, 2018

Today's Rundown

Featured Story

GlaxoSmithKline boss rethinking R&D incentives, as Barron and Sin seek out early and late-stage opportunities

GlaxoSmithKline CEO Emma Walmsley has been in the hot seat for around a year, and while announcing the company's first-quarter results this week had new CSO Hal Barron by her side, as the two hinted at possible changes in R&D incentives and what another new hire made last week could bring to the pipeline.

Top Stories

Mereo pulls IPO, blaming ‘challenging’ stock market conditions

Mereo BioPharma has withdrawn plans to list its stock on Nasdaq. The Novartis-backed biotech set out to bag $80 million (€66 million) to take its brittle bone disease drug into phase 3, only to struggle to raise the money on its desired terms.

Twice rejected by Lilly, Adocia mounts recovery with diabetes drug deal

Adocia has sold the Chinese rights to two diabetes prospects to Tonghua Dongbao Pharmaceuticals for $50 million (€41 million) upfront. The deal sparked a 30% jump in Adocia’s stock price as investors cheered evidence the biotech is gaining momentum 15 months after being dumped by Eli Lilly.

[Sponsored] Can the SEC step in to support small businesses if Congress stalls?

Congress is debating whether to include small businesses in the Senate’s bank bill. But the SEC has an opportunity to take action on SOX 404(b) on its own.

Saniona cleared for second phase of Prader-Willi syndrome trial

Saniona has gotten the go-ahead it needs to continue a midstage trial of its combination therapy for Prader-Willi syndrome, a debilitating genetic disorder that causes insatiable appetite and obesity.

Alder builds case for CGRP migraine drug eptinezumab

Alder BioPharma says data showing its intravenous drug eptinezumab can extend pain-free days between migraines will make it an important option for migraine prevention.

Johnson & Johnson appeal of $151M hip implant ruling succeeds after judge finds talk of Iraqi bribes tainted case

An appeals court has overturned a verdict that ordered Johnson & Johnson to pay $151 million to five people who received its Pinnacle hip implant. The appellate court overruled the prior verdict on the grounds the plaintiffs’ lawyer introduced “inflammatory character evidence” linking J&J to bribes allegedly paid in Saddam Hussein’s Iraq.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Risk-based Approach to Change Management of GxP Systems

Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems.

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams.

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights.

[Whitepaper] The Future of Life Sciences Events Management

Explore a new model for events management, and learn how to deliver more value.

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

Small biopharma companies are conducting almost 50% of the clinical trials in the US today, yet they face unique challenges that large pharma do not. In this paper, we explore some of those challenges, and solutions that can reduce the pressure on small biopharma teams and timelines.

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

Why does confidence matter when outsourcing Fixed-Dose Combination products? Download Halo Pharma’s white paper on the importance of product design, technology, and analyticals tools for FDC.

[Whitepaper] 2018 Life Sciences Trends

What are the biggest trends in life sciences this year?

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.